深圳海域弧菌种类组成、数量分布及其与环境因子的关系研究

研究了深圳海域2008年4月、9月的水体弧菌数量、种类组成及其分布,探讨了弧菌总数及各优势类群的数量分布与环境因子间的相关关系。结果表明:弧菌总数分布具有季节性,东部海域春季(4月)的弧菌数量高于秋季(9月)的,其均值分别为1.50×104,8.89×102CFU/cm3;在西部海域秋季的略高于春季的,其均值分别为5.09×102,2.66×102CFU/cm3;弧菌数量最高值出现在大亚湾(4.40×104CFU/cm3)。弧菌的优势类群具有季节性分布特征:春季特有的优势类群有Vibrio gigantis类似种和V.splendidus类似种,秋季特有的优势类群有V.natriegens类似种;V.alginolyticus类似种是两个季节共有的优势类群,其数量春季高于秋季的。弧菌种类、数量与海水温度、盐度及细菌总数、Chl-a等环境因子有一定的相关性,其中盐度为弧菌种类及数量分布的主要影响因子

福建鲍产业发展形势分析

鲍,素有\"软黄金\"的美誉。自上世纪90年代开始,福建引入皱纹盘鲍与日本盘鲍的杂交鲍并逐渐扩大养殖规模。笔者归纳了福建省鲍的养殖分布及生产情况,结合鲍的消费结构及产业支撑现状发现鲍产业发展过程中的育苗场规划,养殖管理,种质退化,安全用药等方面存在问题,对此提出推进科学养殖,增强环保意识;加强管理制度建设,实现质量监管;加强种质管理,选育新品种;加强技术体系建设;提升产业融合度等建议

荷社稷之重拓探索之渊记国家最高科技奖获得者张存浩院士

2014年1月10日，中共中央、国务院在北京人民大会堂举行2013年度国家科学技术奖励大会。著名物理化学家，中国高能化学激光奠基人、分子反应动力学奠基人之一，中国科学院院士张存浩，荣获2013年度国家最高科学技术奖

荷社稷之重拓探索之渊记国家最高科技奖获得者张存浩院士

2014年1月10日，中共中央、国务院在北京人民大会堂举行2013年度国家科学技术奖励大会。著名物理化学家，中国高能化学激光奠基人、分子反应动力学奠基人之一，中国科学院院士张存浩，荣获2013年度国家最高科学技术奖

基于精确传动比的多级平行轴齿轮减速器齿数设计

以精确保证多级平行轴齿轮减速器的总传动比为设计目标，研究了在给定中心距、总传动比条件下，齿轮各参数之间的数学关系；建立了多级减速器齿轮齿数选择的数学模型；开发了多级齿轮减速器的齿数计算程序，使设计者可以快速确定多级平行轴齿轮减速器各级齿轮的齿数组合，在合理的模数、螺旋角、变位系数取值范围内，保证各级中心距，并精确保证总传动比

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials